Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia

In brief

The purpose of this study is to determine whether FG-4592 is safe and effective in the treatment of anemia in participants with lower risk MDS and low red blood cell transfusion burden.

Key facts

Study ID
NCT03263091
Run by
Kyntra Bio
People needed
184
Starts
2018-01-29
Expected to finish
2023-06-20
Last updated by the study team
2024-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.